Literature DB >> 3880682

Highly sensitive solid-phase immunoenzymometric assay for placental and placental-like alkaline phosphatases with a monoclonal antibody and monodisperse polymer particles.

J L Millán, K Nustad, B Nørgaard-Pedersen.   

Abstract

We have used a mouse monoclonal antibody (H7) to placental alkaline phosphatase (PLAP, EC 3.1.3.1) in developing an immunoenzymometric assay for PLAP and PLAP-like enzymes. The antibody is bound to sheep anti-mouse IgG (Ab2) covalently coupled to tosylated shell-and-core light (1.07 g/cm3) monodisperse polymer particles. Adding the H7-Ab2-polymer particle suspension to a PLAP-containing sample gives maximal binding of the antigen within 10 min. PLAP and PLAP-like enzymes remain active and bound to the solid-phase throughout all assay manipulations, and can thus be saved for future testing. In testing the enzymes for inhibition by L-Phe, L-Phe-Gly-Gly, L-Leu, and L-homoarginine, the effect of all the inhibitors is fully reversible. The assay is highly versatile, and its sensitivity (routinely 0.05 micrograms/L) can be increased 1000-fold by adjusting the sample volume and incubation time (sample volume is irrelevant between 50 microL and 5 mL). We have measured the basal activities of PLAP in men and women and, by using enzyme inhibitors, have characterized it as corresponding to the PLAP-like phenotypes described in normal human testis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3880682

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  2 in total

1.  Gly429 is the major determinant of uncompetitive inhibition of human germ cell alkaline phosphatase by L-leucine.

Authors:  C Hummer; J L Millán
Journal:  Biochem J       Date:  1991-02-15       Impact factor: 3.857

2.  Transgenic mice expressing the tumor marker germ cell alkaline phosphatase: an in vivo tumor model for human cancer antigens.

Authors:  S Narisawa; K A Smans; J Avis; M F Hoylaerts; J L Millán
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.